-+ 0.00%
-+ 0.00%
-+ 0.00%

Annexon Submits Marketing Authorization Application To EMA For Tanruprubart For Treatment Of Guillain-Barré Syndrome

Benzinga·01/08/2026 13:15:00
Listen to the news

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care

BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026

BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart for the treatment of Guillain-Barré syndrome (GBS).